ArticleOrphanet journal of rare diseases2025
Leber hereditary optic neuropathy: utilities and carer burden from British and Irish participants.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeber hereditary optic neuropathy (LHON) is a rare, maternally inherited, mitochondrial disease resulting in sudden, progressive central vision loss. The condition affects numerous aspects of daily life, functioning and overall health-related quality of life (HRQL), which may spillover to carers.
methodsTwo studies were designed to estimate patient utilities associated with varying visual acuity in LHON (study 1) and to explore carer burden (study 2). In study 1, eight LHON health state vignettes (mild vision loss [LogMAR < 0.3] through to light perception [LogMAR ≥ 4]) were valued by the UK and Republic of Ireland (ROI) general pubic using the Health Utilities Index- 3 (HUI-3) and EQ-5D in an online survey (N = 360) and in time trade-off interviews (TTO; n = 120). In study 2, nine carers completed in-depth interviews exploring carer burden, the Care-related Quality of Life instrument (CarerQol), EQ-5D-5L and the Work Productivity and Activity Impairment Questionnaire (WPAI).
resultsStudy 1 demonstrated lower utilities for people with worse visual function. Mild vision loss (LogMAR < 0.3) was rated as 0.84 (HUI-3), 0.79 (EQ-5D) and 0.88 (TTO). Light perception (LogMAR ≥ 4), the most severe health state, was rated as 0.18 (HUI-3), 0.34 (EQ-5D), and 0.36 (TTO). In study 2, qualitative findings revealed substantial burden for many carers and family members. The most prominent impacts were emotional (e.g., guilt, devastation), especially related to the maternal inheritance of LHON. Impacts to carers' daily life, social life and relationships, work, and finances were also described. Standardised measures identified little impact on HRQL (EQ-5D-5L = 0.89), but some carer related burden (CarerQol-7D = 78.4). The WPAI revealed an overall work impairment of 15% and activity impairment of 37%.
conclusionsFindings suggest the HUI-3 may be more sensitive to the HRQL impact of vision loss compared to the EQ-5D and TTO method. The data indicate the potential value of an effective treatment for LHON. Qualitative findings describe the impact of LHON on carers. However, the burden described in the qualitative data was incongruent with quantitative measures, particularly the EQ-5D-5L. This demonstrates the value of conducting mixed-methods research and the importance of selecting measures which capture population-relevant concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.